Eli Lilly and Resilience to Invest $750 Million in Ohio Drug Manufacturing Plant

Eli Lilly and its manufacturing partner Resilience will jointly invest $750 million to expand pharmaceutical production capacity in the United States. The move is aimed at increasing the domestic supply of critical medicines and meeting surging demand for Lilly's key therapies, according to a statement from Resilience.

Investment to Bolster US Supply Chain

The investment will focus on expanding Resilience's operations in the Cincinnati, Ohio region, a project expected to create 400 new high-skilled jobs. A key part of the expansion involves adding manufacturing capabilities for Lilly's KwikPen, an injectable device used for its blockbuster diabetes and obesity treatments.

This initiative reflects a broader industry trend of onshoring pharmaceutical manufacturing to secure domestic supply chains. By increasing U.S.-based production, drugmakers aim to mitigate risks from geopolitical tensions and global logistical disruptions that have impacted various sectors in recent years.

Expanding a Multi-Year Partnership

Ad

This new investment builds upon an existing partnership between the two companies that began in 2023. According to Resilience, the collaboration has already successfully produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats.

Edgardo Hernandez, Lilly’s head of manufacturing, said the expanded partnership reflects the company's significant efforts to keep pace with the rapidly rising demand for its medicines. For investors, this capital deployment signals Lilly's confidence in the long-term revenue potential of its product portfolio, particularly its GLP-1 agonists for diabetes and weight loss.

Lilly's Aggressive Manufacturing Push

The $750 million commitment is part of a much larger capital expenditure strategy for Eli Lilly. The company has announced U.S. capital expansion commitments totaling more than $55 billion since 2020. Lilly plans to break ground on several of its recently announced U.S. manufacturing sites this year, underscoring its aggressive push to scale up production.